Intratumor OX40 stimulation inhibits IRF1 expression and IL‐10 production by Treg cells while enhancing CD40L expression by effector memory T cells
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Treg cells maintain the tumor microenvironment in an immunosuppressive state preventing an effective anti‐tumor immune response. A possible strategy to overcome Treg‐cell suppression focuses on OX40, a costimulatory molecule expressed constitutively by Treg cells while being induced in activated effector T cells. OX40 stimulation, by the agonist mAb OX86, inhibits Treg‐cell suppression and boosts effector T‐cell activation. Here we uncover the mechanisms underlying the therapeutic activity of OX86 treatment dissecting its distinct effects on Treg and on effector memory T (Tem) cells, the most abundant CD4+ populations strongly expressing OX40 at the tumor site. In response to OX86, tumor‐infiltrating Treg cells produced significantly less interleukin 10 (IL‐10), possibly in relation to a decrease in the transcription factor interferon regulatory factor 1 (IRF1). Tem cells responded to OX86 by upregulating surface CD40L expression, providing a licensing signal to DCs. The CD40L/CD40 axis was required for Tem‐cell‐mediated in vitro DC maturation and in vivo DC migration. Accordingly, OX86 treatment was no longer therapeutic in CD40 KO mice. In conclusion, following OX40 stimulation, blockade of Treg‐cell suppression and enhancement of the Tem‐cell adjuvant effect both concurred to free DCs from immunosuppression and activate the immune response against the tumor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces
Rubtsov, Y. P., Rasmussen, J. P., Chi, E. Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W. R., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.017 · Cited by 1,586
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
Koch, M. A., Tucker-Heard, G., Perdue, N. R., Killebrew, J. R., Urdahl, K. B., & Campbell, D. J. (2009) · Nature Immunology · doi:10.1038/ni.1731 · Cited by 1,258
Ito, T., Wang, Y.-H., Duramad, O., Hori, T., Delespesse, G. J., Watanabe, N., Qin, F. X.-F., Yao, Z., Cao, W., & Liu, Y.-J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051135 · Cited by 1,129
Interleukin‐10: new perspectives on an old cytokine
Mosser, D. M., & Zhang, X. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00706.x · Cited by 1,077
Maynard, C. L., Harrington, L. E., Janowski, K. M., Oliver, J. R., Zindl, C. L., Rudensky, A. Y., & Weaver, C. T. (2007) · Nature Immunology · doi:10.1038/ni1504 · Cited by 599
Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549
Heterogeneity of CD4+ memory T cells: Functional modules for tailored immunity
Sallusto, F., & Lanzavecchia, A. (2009) · European Journal of Immunology · doi:10.1002/eji.200939722 · Cited by 348
Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020732 · Cited by 343
Self-citation
Cited by
Eradication of spontaneous malignancy by local immunotherapy
Sagiv-Barfi, I., Czerwinski, D. K., Levy, S., Alam, I. S., Mayer, A. T., Gambhir, S. S., & Levy, R. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4488 · Cited by 361
Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity
Fu, Y., Lin, Q., Zhang, Z., & Zhang, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.010 · Cited by 260
Piconese, S., Timperi, E., Pacella, I., Schinzari, V., Tripodo, C., Rossi, M., Guglielmo, N., Mennini, G., Grazi, G. L., Di Filippo, S., et al. (2014) · Hepatology · doi:10.1002/hep.27188 · Cited by 81
Self-citationCho, M. K., Park, M. K., Kang, S. A., Park, S. K., Lyu, J. H., Kim, D. ‐., Park, H. ‐., & Yu, H. S. (2015) · Parasite Immunology · doi:10.1111/pim.12172 · Cited by 30
Chen, Y.-C., Lee, C. P., Hsiao, C.-C., Hsu, P.-Y., Wang, T.-Y., Wu, C.-C., Chao, T.-Y., Leung, S.-Y., Chang, Y.-P., & Lin, M.-C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228587 · Cited by 21
Metadata
- Authors
- Burocchi, A., Pittoni, P., Gorzanelli, A., Colombo, M. P., & Piconese, S.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2011-11-10
- Volume
- 41
- Issue
- 12
- Pages
- 3615-3626
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2086419629
- Cited by
- 54
- References
- 10
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intratumor OX40 stimulation inhibits IRF1 expression and IL‐10 production by Treg cells while enhancing CD40L expression by effector memory T cells. https://app.cochat.ai/papers/10.1002/eji.201141700
- The paper
- Burocchi, A., Pittoni, P., Gorzanelli, A., Colombo, M. P., & Piconese, S. (2011). Intratumor OX40 stimulation inhibits IRF1 expression and IL‐10 production by Treg cells while enhancing CD40L expression by effector memory T cells. European Journal of Immunology. https://doi.org/10.1002/eji.201141700
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.